In agreement with that, a consensus statement on acromegaly therapeutic outcomes has recommended PEGV as the best medical option for patients with impaired glucose tolerance unresponsive to first-generation of SRLs, due to its beneficial effect on insulin sensitivity and glucose tolerance (15). The gene discussed is INS; the disease is acromegaly.